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Summary
 
NF-
 
k
 
B is an important transcription factor required for T cell proliferation and other immuno-
logical functions. The 
 
NF-
 
k
 
B1
 
 gene encodes a 105-kD protein that is the precursor of the p50
component of NF-
 
k
 
B. Previously, we and others have demonstrated that NF-
 
k
 
B regulates the
 
NF-
 
k
 
B1
 
 gene. In this manuscript we have investigated the molecular mechanisms by which T cell
lines stimulated with phorbol 12-myristate 13-acetate (PMA) and phytohemagglutin (PHA) dis-
play significantly higher levels of 
 
NF-
 
k
 
B1
 
 encoding transcripts than cells stimulated with tumor
necrosis factor-
 
a
 
, despite the fact that both stimuli activate NF-
 
k
 
B. Characterization of the
 
NF-
 
k
 
B1
 
 promoter identified an Egr-1 site which was found to be essential for both the PMA/
PHA-mediated induction as well as the synergistic activation observed after the expression of
the RelA subunit of NF-
 
k
 
B and Egr-1. Furthermore, Egr-1 induction was required for endog-
enous 
 
NF-
 
k
 
B1
 
 gene expression, since PMA/PHA-stimulated T cell lines expressing antisense
Egr-1 RNA were inhibited in their ability to upregulate 
 
NF-
 
k
 
B1
 
 transcription. Our studies in-
dicate that transcriptional synergy mediated by activation of both Egr-1 and NF-
 
k
 
B may have
important ramifications in T cell development by upregulating 
 
NF-
 
k
 
B1
 
 gene expression.
 
T
 
cell activation results in a rapid activation of NF-
 
k
 
B
(1, 2) which appears to play an important role in T cell
proliferation, partly because of the involvement of this tran-
scription factor in the upregulation of the IL-2 and cognate
receptor (IL-2R) genes (3). NF-
 
k
 
B was originally described to
be composed of heterodimeric subunits of p50 and p65
proteins (1, 2) and is typically found in the cytoplasm of
cells as an inactive precursor complex with an inhibitor
protein, I
 
k
 
B (4). The 
 
NF-
 
k
 
B1
 
 gene product p105 is pro-
cessed into the DNA-binding subunit of p50 through a
mechanism that requires serine phosphorylation (5) and the
induction of an ATP-dependent ubiquitin–proteasome
pathway (6, 7). Cellular activation leads to an increase in
 
NF-
 
k
 
B1
 
 transcripts, p105 processing, and subsequent p50
accumulation in both fibroblasts and in T cells (5, 8).
Although little is known about the regulation of 
 
NF-
 
k
 
B1
 
 in T lymphocytes, its expression has been demon-
strated to be essential for proliferation after costimulation
through CD2 or CD28 receptors (9). Recently, it has been
demonstrated that lymphocytes derived from p50
 
2
 
/
 
2
 
-defi-
cient mice display defects in immune responses (10). In ad-
dition Sha et al. (10) noted that T cells derived from these
animals were unable to effectively proliferate in response to
TCR and CD28 costimulation. Although disruption of the
 
NF-
 
k
 
B1
 
 gene did not result in lethality, possibly because
 
NF-
 
k
 
B2
 
/p52 could substitute for p50, these studies strongly
suggest that the p50 DNA-binding component of NF-
 
k
 
B
is critical for T cell proliferation.
Analysis of the 
 
NF-
 
k
 
B1
 
 promoter revealed several NF-
 
k
 
B
DNA-binding sites within the upstream regulatory region
which are capable of binding p50 homodimers, p50/p65,
or p50/c-Rel heterodimers and, in part, account for the
ability of NF-
 
k
 
B to regulate 
 
NF-
 
k
 
B1
 
 gene expression (11,
12). Although the 
 
NF-
 
k
 
B1
 
 promoter has been shown to
require NF-
 
k
 
B for activity, it is presently unclear whether
NF-
 
k
 
B needs other transcription factors to mediate a tran-
scriptional response. This is especially important because on
many responsive promoters NF-
 
k
 
B alone is insufficient at
activating transcription (2). T cell stimulation mediated by
the addition of either PMA and PHA or TNF-
 
a
 
 results in
an increase in 
 
NF-
 
k
 
B1
 
 expression (13). Both stimuli activate
NF-
 
k
 
B nuclear translocation and DNA-binding within 15
to 30 min (14); however, phorbol esters in combination
with mitogens result in a greater accumulation of 
 
NF-
 
k
 
B1
 
transcripts (11, 13). Our research demonstrates that full
PMA/PHA-mediated activation of the 
 
NF-
 
k
 
B1
 
 promoter
not only required the NF-
 
k
 
B transcription factor, but also
the activation of the early growth response gene product
(Egr-1)
 
1
 
. Egr-1, also known as NGFI-A, Zif268, Krox-24,
and Tis 8, is transiently induced during the activation of T
 
1
 
Abbreviations used in this paper:
 
 Egr-1; early growth response gene prod-
uct; EMSA, electrophoretic mobility shift assay.
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cells from the G
 
0
 
 to G
 
1
 
 phase in response to various cellular
stimuli (15), has been recently demonstrated to be required
for T cell proliferation, and is known to regulate transcrip-
tion of several genes (15–17). Our data establishes Egr-1
and RelA as important transcription factors capable of syn-
ergistically transactivating the 
 
NF-
 
k
 
B1
 
 promoter.
 
Materials and Methods
 
Cell Culture and Transient Transfection Analysis.
 
CEM cells were
cultured in RPMI 1640 medium containing 10% FCS and antibi-
otics. Cells were stimulated by supplementing their growth me-
dium with either PMA and PHA (Sigma Chemical Co., St. Louis,
MO) to a final concentration of 50 ng/ml and 5 
 
m
 
g/ml, respec-
tively, or TNF-
 
a
 
 (10 ng/ml; Promega Corp., Madison, WI). Tran-
sient transfections by electroporation (11) and luciferase or chloram-
phenicol  acetyl-transferase assays were performed as previously
described (11, 18, 19).
 
Plasmid Constructs and Site-directed Mutagenesis.
 
Both the 
 
NF-
 
k
 
B1
 
 promoter constructs, p50HS- and p50SS-CAT, were previously
described (11). The SpS-, HiS-, and AS-CAT constructs were gen-
erated by digesting the p50HS-CAT reporter with HindIII, and
SphI, HinfI, or ApoI, respectively. The SSLUC reporter plasmid was
generated by cloning the StuI/SmaI fragment from p50HS-CAT
into the pGL2 basic reporter containing the luciferase gene (Promega
Corp.). The StuI/SmaI fragment of the 
 
NF-
 
k
 
B1
 
 promoter was sub-
jected to site-directed mutagenesis using a two-staged PCR (20).
The mNLUC construct, containing the disrupted 289-bp NF-
 
k
 
B
site, was made using a 5
 
9
 
 primer (5
 
9
 
-ATGTAACTGAGACAC-
GCTTAAATGGAATA-3
 
9
 
) and a 3
 
9
 
 primer (5
 
9
 
-AGGCCAT-
CAGCGCCGCGCCATGGCCGCA-3
 
9
 
) in the first round of
amplification and two internal primers (5
 
9
 
-AGGCGCTTCCT-
GGAAGCTTGAATACCGGCTCCAG-3
 
9
 
 and 5
 
9
 
-CTGGAG-
CCGGTATTCAAGCTTCCAGGAAGCGCCT-3
 
9
 
) which mu-
tated the 
 
k
 
B element to a HindIII site. The 
 
NF-
 
k
 
B1
 
 promoter
sequences containing a site-directed mutation within the Egr-1
DNA binding site (mELUC) was created using the same 5
 
9
 
 and 3
 
9
 
primers described above plus two internal primers (5
 
9
 
-GCGCAC-
GCAGCGAATTCGGGAGGTAGGGTC-3
 
9
 
) and (5
 
9
 
-GACCCT-
ACCTCCCGAATTCGCTGCGTGCGC-3
 
9
 
) which destroyed
both the SP1/Egr-1 motif and created a unique EcoRI site. The
mNELUC construct was created by mixing the mutant Egr-1
oligos described above and using the mNF-
 
kB fragment as a tem-
plate. The PCR amplified NF-kB1 promoter fragments were cloned
into the SSLUC construct by replacing the wild-type PvuII/SmaI
fragment with the corresponding site-directed mutant promoter
sequences. Nucleotide sequences of mN, mE, and mNELUC
constructs were confirmed by sequence analysis.
Northern Blot and Electrophoresis Mobility Shift Analysis. Total cel-
lular  RNA was isolated from CEM cells using the RNeasy total
RNA kit (Qiagen, Inc., Chatsworth, CA). Northern blot analysis
was performed as previously described (11). Nuclear extracts were
isolated and electrophoresis mobility shift analyses (EMSAs) were
performed as previously described (11, 18). Oligonucleotides cor-
responding to the NF-kB1 promoter Egr-1 DNA binding site
(59-TCGACTCCCGCCCCCGCTGCG-39 and 59-TCGACGC-
AGCGGGGGCGGGAG-39) were radiolabeled using a-[32P]dCTP
and the Klenow fragment of DNA polymerase I. For antibody
super shift assays and competition experiments, nuclear extracts
were preincubated (10 min, room temperature) with either 1 mg of
antiserum or with a nonradioactive double stranded oligonucle-
otide before the addition of the radiolabeled gel shift probe. The
mutant Egr-1 probe (annealed 59-TCGACTCCCGAATTCG-
CTGCG-39 and 59-TCGACGCAGCGAATTCGGGAG-39) was
used in competition assays. The Egr-1–specific antibody (SC
No. 189) was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA).
Generation of Stable Cell Lines. The full-length human Egr-1
cDNA was cloned into the EcoR1 site of the CMV-5 expression
vector in the antisense orientation. CEM cells were cotransfected
with either CMV-AsEgr-1 or with the CMV-5 control vector in the
presence of pcDNA-3.1 Neo (Invitrogen, San Diego, CA). Trans-
fected cells were grown in complete RPMI-1640 medium sup-
plemented with 1.5 mg/ml of Geneticin (GIBCO BRL, Gaithers-
burg, MD) and resistant clones were isolated. RNase protection
assays were performed using the RPA II kit (Ambion, Inc., Aus-
tin, TX) to ensure that the CEM/AsEgr-1 cells were expressing
the CMV-driven antisense human Egr-1 transcript.
Results and Discussion
Differential Expression of NF-kB1 mRNA After PMA/
PHA– or TNF-a–Stimulation. To determine whether dif-
ferential expression of NF-kB1 mRNA was observed after
stimulation by PMA and PHA or TNF-a, Northern blot
analysis was performed on total cellular RNA isolated from
the human T cell line, CEM. As shown in Fig. 1 A, NF-
kB1 mRNA began to accumulate within 1 h of stimulation
with PMA and PHA, and by 4 h a significant induction
(10-fold) was observed in CEM cells. Although TNF-a–stim-
ulated cells also displayed increases in NF-kB1 transcripts
with similar kinetics, a substantially lower accumulation of
mRNA was observed over the 4-h time course.
Identification of the NF-kB1 Promoter Region Required for
PMA/PHA-Responsive Upregulation. To determine whether
the increase in NF-kB1 mRNA, seen in Fig. 1 A, was due
to transcriptional upregulation of the promoter and not due
to PMA/PHA-induced message stabilization, CEM cells
were transiently transfected with the p50HS-CAT NF-kB1
promoter construct and stimulated with either PMA/PHA
or TNF-a for 24 h. As shown in Fig. 1 B, the NF-kB1
promoter (p50HS-CAT) was strongly activated in CEM
cells after PMA/PHA stimulation, but only weakly after
TNF-a addition, suggesting that PMA/PHA-mediated ac-
tivation of the NF-kB1 promoter was through a transcrip-
tion-dependent mechanism.
To localize the PMA/PHA-responsive region within the
NF-kB1 promoter, a series of deletion promoter constructs
were made. CEM cells were transiently transfected with
each reporter construct and then either stimulated with
PMA/PHA or with TNF-a. As shown in Fig. 1 B, no sig-
nificant difference in stimulation was observed between the
HS-, the SS-, or the SpS-CAT constructs. However, the
HiS-CAT reporter, which lacked the 2289 NF-kB site,
displayed a significant decrease in NF-kB1 promoter activ-
ity after stimulation by either PMA/PHA or TNF-a. The
AS-CAT reporter, lacking both the 2103 and 211 kB sites,
was greatly diminished in response to PMA/PHA– and
TNF-a–mediated activation (Fig. 1 B). Collectively, this
data indicates that the region between the SphI site (2425)493 Cogswell et al.
and the ApoI site (29) was critical for both inducers, but
that PMA/PHA stimulation resulted in a higher fold acti-
vation than TNF-a. Based on the deletion analysis of the
NF-kB1 promoter, these results suggest that both stimuli may
use NF-kB, but that the PMA/PHA stimulation must acti-
vate additional transcription factors not induced by TNF-a.
The NF-kB1 Promoter Contains an Egr-1 Consensus Site and
T Cells Stimulated with PMA and PHA, but not TNF-a, Display
Egr-1 DNA Binding. Computer analysis of the SphI/ApoI
fragment of the NF-kB1 promoter identified potential
DNA-binding motifs for five different transcription factors
including AP-1, E2F, Egr-1, NF-kB, and SP1. Of these,
NF-kB, Egr-1, and AP-1 are known to display increased
transactivation potential after PMA stimulation (2, 15, 21).
Since PMA/PHA and TNF-a both activated NF-kB, we ex-
cluded this transcription factor as the nuclear factor re-
sponsible for differentially regulating the NF-kB1 promoter.
In addition, the putative AP-1 site located in the NF-kB1
promoter was not found to affect PMA-induced transac-
tivation of the NF-kB1 promoter (12). To test whether ex-
tracts from PMA/PHA-stimulated cells would display Egr-1
binding, EMSAs were performed. As shown in Fig. 2 A, a
32P double stranded oligonucleotide probe corresponding
to the 68-bp Egr-1 site within the NF-kB1 promoter bound
a nuclear protein which was present in PMA/PHA-stimu-
lated cell extracts (lane 2), but not in unstimulated cell ex-
tracts (lane 1). This DNA–protein complex could also be
Figure 1. NF-kB1 gene expression and
promoter analysis in CEM cells after PMA/
PHA or TNF-a stimulation. (A) RNAs
were isolated from CEM cells after addition
of either PMA/PHA (50 ng and 5 mg/ml)
or TNF-a (10 ng/ml) over the time course
indicated. RNAs were detected using a 32P-
labeled NF-kB1-specific probe. Transcripts
encoding NF-kB1 were quantitated by den-
sitometric scanning of autoradiograms and
the fold accumulation of mRNAs were cal-
culated after normalization to b-actin. (B)
Schematic of the NF-kB1 promoter depict-
ing the Egr-1 and NF-kB binding sites.
CEM cells were transfected with either the
HS-CAT reporter or with various deletion
constructs (SS-, SpS-, HiS-, and AS-CAT).
18 h after transfection, cells were stimulated
with either PMA/PHA (50 ng and 5 mg/
ml) or TNF-a (10 ng/ml) and CAT activity
was analyzed. Transfection experiments
were performed in triplicate and the mean
fold induction and the standard deviations
are shown.
Figure 2. Identification of an Egr-1 DNA binding site within the NF-
kB1 promoter. (A) Nuclear extracts were isolated from CEM cells after a
2 h PMA/PHA stimulation in either the absence or presence of cyclohex-
imide (50 mg/ml, 30 min pretreatment). Nuclear extracts (5 mg) were in-
cubated with a 32P-labeled probe corresponding to the 68-bp Egr-1 site.
Competition assays and antibody supershift experiments were performed
by preincubating nuclear extracts (15 min) with either unlabeled mutant
Egr-1 (mEgr-1) or wild-type Egr-1 oligonucleotide (50 ng total) before
the addition of probe. Lane 1, unstimulated cells; lane 2, PMA/PHA for
2 h; lane 3, PMA/PHA 1 wild-type Egr-1 oligo; lane 4, PMA/PHA 1
mEgr-1 oligo; lane 5, PMA/PHA 1 Egr-1–specific antibody; lane 6, pre-
treatment with cycloheximide (30 min) 1 PMA/PHA for 2 h. SS indi-
cates the position of the Egr-1 1 antibody supershift complex; NS identi-
fies nonspecific bands. (B) Nuclear proteins from CEM cells were isolated
after the addition of either PMA/PHA or TNF-a over the indicated time
course and EMSAs were performed using the 32P-labeled Egr-1 site. Note
that the unbound 32P-labeled probe is not shown in both A and B.494 Egr-1 and NF-kB Control T Cell–activated NF-kB1 Transcription
competed with an excess of wild-type unlabeled oligonu-
cleotide (lane 3), but not by equal concentrations of a corre-
sponding mutant Egr-1 site (lane 4). Moreover, this complex
contained Egr-1 protein since incubation with an Egr-1–spe-
cific antibody completely supershifted the nuclear protein
bound to the 32P-probe (lane 5). Pretreatment with cyclo-
heximide, which has been previously demonstrated to
block PMA-mediated increases in Egr-1 protein (15), pre-
vented the detection of Egr-1–specific binding (lane 6). Al-
though we do not effectively detect SP1 binding under our
EMSA conditions (Fig. 2 A), we observed constitutive SP1
binding in nuclear extracts isolated from CEM cells using a
modified binding protocol (data not shown). Since SP1
binding to the 268 site was constitutive and completely in-
dependent of cellular stimulation mediated by either PMA/
PHA or TNF-a (data not shown), we chose to focus on
the inducible binding of the Egr-1 transcription factor.
To elucidate whether differential Egr-1 binding was ob-
served in T cells after the addition of either PMA/PHA or
TNF-a, nuclear proteins were isolated from stimulated
CEM cells over a 4 h time course and EMSAs were per-
formed using the NF-kB1 Egr-1 consensus site. After stim-
ulation with PMA/PHA, Egr-1 binding begins to appear
within 30 min and continues to increase at both 1 and 2 h
with a slight decrease seen at 4 h (Fig. 2 B). Interestingly,
no Egr-1 binding was observed in CEM cell extracts after
TNF-a stimulation (Fig. 2 B). However, both PMA/
PHA– and TNF-a–stimulated CEM cells demonstrated
NF-kB–specific binding after the addition of each inducer,
confirming that CEM cells were capable of responding to
TNF-a (data not shown). Identical results to those ob-
tained in the CEM cell line were demonstrated in Jurkat
T cells (data not shown). Collectively, these results indicate
that the 268 site located in the NF-kB1 promoter is capa-
ble of binding the Egr-1 transcription factor and that, un-
like PMA/PHA stimulation, TNF-a fails to stimulate Egr-1
binding in T cell lines.
Efficient PMA/PHA-Responsive Activation of the NF-kB1
Promoter Requires the Egr-1 DNA Binding Site.  To determine
whether Egr-1 is required for PMA/PHA responsive acti-
vation of the NF-kB1 promoter, site-directed mutagenesis
was performed. Since the NF-kB1 promoter is regulated
directly by NF-kB (11, 12), we chose to mutate the 2289
kB motif alone or in combination with the 268 Egr-1
binding site. The four luciferase NF-kB1 promoter con-
structs included (a) SSLUC, the wild-type construct, (b)
mNLUC, which contained a mutated NF-kB site at posi-
tion 2289, (c) mELUC, which contained the disrupted 68-bp
Egr-1 site, and (d) mNELUC, which contained mutated
NF-kB and Egr-1 sites. As shown in Fig. 3 A, site-directed
mutagenesis of the Egr-1 binding element (mELUC) sig-
nificantly diminished PMA/PHA-responsive activation of
the NF-kB1 promoter, but had very little or no effect on
TNF-a–mediated stimulation. In contrast, mutating the
NF-kB 2289 site alone had very little effect on either
PMA/PHA– or TNF-a–induced activation (data not shown).
These results in conjunction with the promoter deletion
studies (shown in Fig. 1 B) would strongly suggest that
other kB binding sites (namely 2103 and 211) are impor-
tant for transcriptional activation. Recently, McElhinny et al.
Figure 3. The Egr-1 DNA binding site is required for PMA/PHA–responsive activation and for transcriptional synergy mediated by RelA and Egr-1. (A)
CEM cells were transfected with either the wild-type NF-kB1 promoter (SSLUC) or with each of the site-directed mutants including (a) mNLUC,
which contained a mutated NF-kB site at position 2289, (b) mELUC, which contained a disrupted 68-bp Egr-1 site, and (c) mNELUC, which con-
tained mutated NF-kB and Egr-1 sites, and 18 h later cells were stimulated with either PMA/PHA or TNF-a. 24 h after stimulation, cell extracts were
harvested and assayed for luciferase activity. (B) CEM cells were co-transfected with either the SSLUC construct or with mutant reporters (mN, ME,
mNE; 5 mg each) and with various expression vectors (5 mg) including an empty vector control, RelA, Egr-1, or RelA plus Egr-1. Cells were harvested
48 h after transfection and luciferase activities were determined. (C) The SSLUC construct was transfected into CEM cells along with either the vector
control or with an Egr-1 expression construct. 18 h after transfection, cells were either left untreated or stimulated with PMA/PHA or TNF-a. Cells
were harvested 24 h after stimulation and extracts were analyzed for luciferase activity. All transfection assays were performed in triplicate in three inde-
pendent experiments.495 Cogswell et al.
(22) demonstrated that the 211 NF-kB site was required
for HIV-mediated induction of NF-kB1 promoter in mono-
cytes. Although the 2289 motif is probably not the only
functional NF-kB motif, site-directed mutagenesis of both
the Egr-1 and NF-kB elements (mNELUC), resulted in a
further decrease in PMA/PHA-responsive stimulation com-
pared to the mELUC construct (Fig. 3 A). Taking into ac-
count that mutagenesis of the Egr-1 site in the NF-kB1
promoter significantly diminished PMA/PHA-responsive
stimulation, these results indicate that the 268 Egr-1 site
plays an important role in the activation of this gene in T
lymphocytes.
NF-kB and Egr-1 Transcription Factors Synergistically Trans-
activate the NF-kB1 Promoter. To further explore the abil-
ity of each of these transcription factors to activate the NF-
kB1 promoter, the wild-type as well as the site-directed
mutant reporters were cotransfected with the empty ex-
pression plasmid or with constructs encoding either RelA,
the p65 subunit of NF-kB, Egr-1, or a combination of
both. As shown in Fig. 3 B, the SSLUC reporter was
strongly transactivated after cotransfection with the RelA
encoding expression construct, but only weakly activated
by the overexpression of Egr-1. Interestingly, transfection
with both RelA and Egr-1 resulted in a potent synergistic
transactivation of the NF-kB1 promoter. Although the
2289  kB site was important for RelA-mediated transacti-
vation, mutagenesis of this element did not affect activation
by Egr-1, nor did it affect RelA/Egr-1 synergy (Fig. 3 B). This
result would suggest that, in the presence of Egr-1 binding,
other kB sites located within the NF-kB1 promoter are
used for the synergistic response. Unlike the mNLUC re-
porter, mutagenesis of the Egr-1 site (mELUC) resulted in
a significant reduction in RelA-, Egr1-, and RelA/Egr1-
mediated activation of the NF-kB1 promoter (Fig. 3 B).
However, disruption of both the 2289 and 268 sites
(mNELUC) did not further diminish RelA/Egr-1–medi-
ated synergy. This would suggest that overexpression of
both of these transcription factors may indirectly lead to the
activation of the NF-kB1 promoter by upregulating other
trans-acting elements, or that Egr-1 (like NF-kB) recog-
nizes other DNA-binding sites within the NF-kB1 pro-
moter. Collectively, co-transfection studies strongly suggest
that the Egr-1 DNA binding site is critical for both Egr-
1–mediated transactivation and for RelA/Egr-1-dependent
synergy. Although the Rel homology domain of RelA has
been shown to be responsible for protein–protein interac-
tions with transcription factors outside of the NF-kB/Rel
family (23–26), we were unable to demonstrate a physical
interaction between RelA and Egr-1, nor were we able to
generate synergistic transactivation mediated by these fac-
tors using either a 33–NF-kB or 33-Egr-1 CAT reporter
(data not shown).
Egr-1 Complements TNF-a to Stimulate the NF-kB1 Pro-
moter. To determine whether the difference between PMA/
PHA– and TNF-a–stimulated NF-kB1 gene expression was
due to the inability of TNF-a to activate Egr-1, CEM cells
were transfected with the SSLUC reporter along with the
empty vector control or with the Egr-1 expression con-
struct and 24 h later cells were stimulated with PMA/PHA
or TNF-a. As shown in Fig. 3 C, the fold increase be-
tween cells transfected with the vector control or with the
Egr-1 expression construct was comparable to previous ex-
periments, while PMA/PHA-stimulated cells (coexpressing
Egr-1) displayed the highest level of NF-kB1 activation.
Interestingly, cells transfected with Egr-1 and stimulated
with TNF-a displayed a significant increase in promoter
activity, compared to TNF-a–stimulated cells transfected
with the vector control. The ability of Egr-1 to augment
TNF-a–mediated activation of the NF-kB1 promoter was
a direct effect since the transcriptional synergy was not ob-
served with the mELUC construct containing the dis-
rupted Egr-1 binding site (data not shown). These results
demonstrate that the Egr-1 transcription factor can com-
plement TNF-a–mediated stimulation of the NF-kB1 pro-
moter. Furthermore, our data suggests that the inability of
TNF-a to activate Egr-1 may account for the difference
between PMA/PHA– and TNF-a–mediated NF-kB1 gene
expression in T cells.
Endogenous NF-kB1 Gene Expression Is Affected in T Cells
Expressing Antisense Egr-1 RNA. To determine the im-
portance of the Egr-1 transcription factor on endogenous
NF-kB1 gene expression, we developed a CEM cell line
which constitutively expressed antisense human Egr-1 RNA.
Total RNAs were isolated from either CEM/AsEgr-1 cells
(which express the human Egr-1 antisense RNA) or from
CEM/CMV control cells (which harbor the empty expres-
sion vector) after the addition of either PMA/PHA or
TNF-a over the time course indicated. As shown in Fig.
4 A, CEM/AsEgr-1 cells did not display significant in-
creases in NF-kB1 transcripts until 4 h after PMA/PHA
addition, while the control cells (CEM/CMV) responded
within 1 to 2 h with similar kinetics as the parental CEM
cell line (Fig. 1 A). Interestingly, TNF-a–stimulated CEM/
AsEgr-1 cells demonstrated a reduction in NF-kB1 tran-
scripts 30 min after activation. Although TNF-a does not
activate Egr-1, it would appear that under conditions in
which endogenous Egr-1 levels are reduced (as with CEM/
AsEgr-1 cells), TNF-a stimulation represses NF-kB1 tran-
scription (Fig. 4 A). Although the level of Egr-1 protein in
the CEM/AsEgr-1 cells after PMA/PHA stimulation was
significantly lower (fivefold) than protein levels observed in
the control line, the antisense Egr-1 transcripts were not
able to completely block PMA/PHA-mediated increases in
Egr-1 protein (Fig. 4 B). Perhaps for this reason CEM/
AsEgr-1 cells are still able to display PMA/PHA-responsive
upregulation of NF-kB1 transcripts but with slower kinetics.
In this paper we have demonstrated that to achieve full
activation of the NF-kB1 promoter, T cell signals require not
only the activation of NF-kB, but also the Egr-1 transcrip-
tion factor. Interestingly, it appears that the potent activa-
tion of NF-kB DNA binding activity by TNF-a is insuffi-
cient at inducing high levels of NF-kB1 transcription. This
is consistent with the recent report that activation of NF-kB
binding by TNF-a is insufficient at activating VCAM-1496 Egr-1 and NF-kB Control T Cell–activated NF-kB1 Transcription
transcription in some cells, but the co-activation of NF-kB
and IRF-1 in endothelial cells functions to stimulate tran-
scription (27, 28). Moreover, like NF-kB, Egr-1 is a rela-
tively poor activator of NF-kB1 transcription. Thus, it is
the combined action of NF-kB and Egr-1, both of which
alone result in weak activation, that functions to synergisti-
cally stimulate the NF-kB1 promoter. A number of NFkB-
responsive genes have been characterized and found to require
Egr-1 DNA binding motifs for maximum transactivation.
Such genes include TNF-a, IL-2, and ICAM-1 (17, 29, 30).
In T cells, TNF-a does not fully upregulate its own promoter,
presumably because of the inability of cytokines to activate
Egr-1 (17). However, primary human fibroblasts and mac-
rophage cell lines display dramatic increases in Egr-1 after
TNF-a stimulation (15). Collectively, these studies would
suggest that the synergistic potential mediated by the NF-
kB and Egr-1 transcription factors are not only restricted
by the type of stimuli, but also may depend on the particu-
lar cell type. Thus, it appears that the functional interaction
of NF-kB and Egr-1 in the context of a promoter is likely
to mediate critical aspects of T cell signaling and potentially
other important aspects of cellular growth control. The po-
tent synergy between NF-kB and Egr-1 may explain, at
least partially, the requirements for these transcription fac-
tors in T cell proliferation with NF-kB1 being a critical
downstream target for Egr-1.
Figure 4. Egr-1 is required for endoge-
nous NF-kB1 gene expression. (A) Total
RNAs were isolated from CEM/CMV
control cells or from CEM/AsEgr-1 cells
stimulated with either PMA/PHA or
TNF-a over a 4 h period. RNAs were de-
tected using a 32P-labeled NF-kB1 specific
probe. (B) Total proteins were isolated from
CEM/CMV or CEM/AsEgr-1 cells after
the addition of either PMA/PHA or TNF-a.
Proteins were subjected to PAGE and ana-
lyzed using an Egr-1–specific antibody and
enhanced chemiluminescent assay. NS, shows
the presence of a nonspecific band and
demonstrates that equal amounts of protein
were loaded in each lane.
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